Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 41 | 0.85 |
| pathways Reactome | 2 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 11354
Sealed predictions
- EIF2AK1 in dopamine neurons, braak+0.46 (p 0.212) → -0.52 (p 0.154)receipt 11361
Swarm cases
receipt 11361: EIF2AK1 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.956, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.06 (p 0.814, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.677, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.10, sign flips 8; without severely affected donors -0.01 (p 0.956, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EIF2AK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts